ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

VIBERZI
Colorectal disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

VIBERZI CIV

Generic Name and Formulations:
Eluxadoline 75mg, 100mg; tabs.

Company:
Allergan

Therapeutic Use:

Indications for VIBERZI:

Treatment of irritable bowel syndrome with diarrhea (IBS-D).

Adult:

Take with food. 100mg twice daily. Patients with mild or moderate hepatic impairment, receiving concomitant OATP1B1 inhibitors (see Interactions), or unable to tolerate 100mg dose: 75mg twice daily.

Children:

Not established.

Contraindications:

Without a gallbladder. Biliary duct obstruction. Sphincter of Oddi disease or dysfunction. Alcoholism, alcohol abuse/addiction, or >3 alcoholic drinks/day. History of pancreatitis or structural disease of the pancreas (including pancreatic duct obstruction). Severe hepatic impairment. History of chronic or severe constipation or sequelae from constipation. Mechanical GI obstruction.

Warnings/Precautions:

Discontinue if severe constipation develops. Increased risk of sphincter of Oddi spasm and pancreatitis; monitor for new or worsening abdominal pain (eg, acute epigastric or biliary), with or without nausea/vomiting, or associated with liver or pancreatic enzyme elevations; discontinue and treat if symptoms occur; do not restart if biliary duct obstruction or sphincter of Oddi spasm develops. Assess alcohol intake prior to initiation. Pregnancy. Nursing mothers.

Interactions:

Avoid excessive alcohol. Potentiated by OATP1B1 inhibitors (eg, cyclosporine, gemfibrozil, atazanavir, lopinavir, ritonavir, saquinavir, tipranavir, rifampin, eltrombopag). May be potentiated by strong CYP inhibitors (eg, ciprofloxacin, gemfibrozil, fluconazole, clarithromycin, paroxetine, bupropion); monitor. Increased risk for constipation with alosetron, anticholinergics, opioids; avoid. May potentiate OATP1B1 and BCRP substrates (eg, rosuvastatin: use lowest effective dose of rosuvastatin) or CYP3A substrates with narrow therapeutic index (eg, alfentanil, cyclosporine, ergots, fentanyl, pimozide, quinidine, sirolimus, tacrolimus); monitor.

Pharmacological Class:

Mu-opioid receptor agonist.

Adverse Reactions:

Constipation, nausea, abdominal pain; sphincter of Oddi spasm, pancreatitis.

Generic Availability:

NO

How Supplied:

Tabs—60

Sign Up for Free e-newsletters